['colorectal cancer', 'chemotherapy-induced neutropenia']
['gm1', 'placebo', 'mfolfox6 or xelox']

        Inclusion Criteria:

          -  Age: 18-75 years old, male or female

          -  Histologically confirmed diagnosis of colorectal adenocarcinoma with a phase II or III
             disease, within 2 months from radical resection, and intends to receive 6 months of
             adjuvant chemotherapy with mFOLOFX6 or XELOX, without adjuvant radiation indications

          -  No prior any level of peripheral nerve system disease

          -  Patients have not received any other possible neurotoxic-reaction-causing drugs (such
             as oxaliplatin, cisplatin and paclitaxel drugs etc)

          -  With the capability to accurately record the occurrence and severity of neurotoxicity
             by questionnaire

          -  With normal functions of major organs

          -  No contraindication to chemotherapy

          -  Life expectancy ≥ 3 months

          -  Patients have provided a signed Informed Consent Form

        Exclusion Criteria:

          -  Patients who received radical resection, but are expected not be able to complete 6
             months of adjuvant chemotherapy

          -  Patients who receive palliative chemotherapy

          -  Patients who need adjuvant or palliative radiotherapy during chemotherapy

          -  Be allergic to GM1

          -  Hereditary abnormal metabolism of glucose and lipid

          -  Doctors believe that patients are not suitable for receiving GM1 treatment

          -  With confirmed history of neurological or psychiatric disorders, including epilepsy
             and dementia

          -  With concomitant diseases that will seriously harm the patients' safety or impact the
             completion of the study

          -  Patients (male or female) have fertility possibility but not willing or not to take
             effective contraceptive measures
      